3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
2
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Rectal Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Colorectal Neoplasms
1
Interventions
Cisplatin
10
Gemcitabine
7
Fluorouracil
7
Carboplatin
7
Capecitabine
7
venetoclax
5
Oxaliplatin
5
Cyclophosphamide
4
sintilimab
3
Radiotherapy
3
Neoadjuvant Therapy
3
Dexamethasone
3
Bevacizumab
3
Azacitidine
3
130-nm albumin-bound paclitaxel
3
trametinib
2
regorafenib
2
pembrolizumab
2
nimotuzumab
2
fludarabine
2
disitamab vedotin
2
daratumumab
2
dabrafenib
2
camrelizumab
2
blinatumomab
2
apatinib
2
Trastuzumab
2
Temozolomide
2
Radiotherapy, Intensity-Modulated
2
Radiation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Not yet recruiting
×
Water
×
Clear all
NCT07321847
2026-01-07
INJECTABL-3
Immunophotonics, Inc.
Phase 2/3
Not yet recruiting
717 enrolled